Published in Healthcare Mergers, Acquisitions and Ventures Week, March 24th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at VaxGen.
Report 1: VaxGen, Inc., (VXGN.PK) announced that the U.S. Department of Health & Human Services (HHS) has terminated for default the company's contract to provide 75 million doses of a modern anthrax vaccine for civilian biodefense.
HHS based the decision on its determination that VaxGen "failed to successfully cure the condition endangering performance and failed to" meet a milestone imposed by HHS that required VaxGen to initiate a clinical trial of the vaccine candidate by December...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.